Skip to main content
CHRS logo

Coherus Oncology, Inc.

CHRSNASDAQHealthcareBiotechnology

$1.01Today:- (-)1Y −37.13%

As of Oct 26, 2026 close

Market cap
$156.37M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.94$2.62
Volume (live)
-
Avg. volume (3M)
1.53M

Coherus Oncology (CHRS) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Coherus Oncology used $138.51M of cash in operating activities. Free cash flow was −$138.51M.

Coherus Oncology Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Coherus Oncology, Inc. (CHRS) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income168.0228.51-237.89-291.75-287.10132.2489.83-209.41-238.29
Depreciation & Amortization3.925.283.793.703.452.893.263.243.40
Deferred Income Tax0.000.000.000.009.440.00-0.063.560.45
Stock Based Compensation16.9727.8043.1150.7451.3638.1633.5934.8036.07
Change in Working Capital-5.8455.89-36.83-79.2642.36-34.65-113.9310.30-5.13
Change in Accounts Receivable93.56149.35-150.6613.0534.06-15.22-141.998.281.86
Change in Inventory-17.11-31.95-46.72-47.25-6.25-38.36-48.18-5.48-0.15
Change in Accounts Payable-19.56-3.9423.76-4.540.87-9.829.89-0.53-4.45
Change in Other Working Capital-10.330.0834.10-16.44143.0528.7566.368.04-2.39
Other Operating Activities-10.330.0852.9375.45143.0512.0215.66-1.753.22
Net Cash from Operating Activities-138.51-20.44-174.88-241.12-37.43154.1528.36-159.27-200.29
Investing Activities
Capital Expenditures0.000.00-0.29-2.04-1.29-7.23-12.90-0.79-4.57
Acquisitions-12.50-12.507.000.001.290.001.66-0.700.00
Purchases of Investments-103.840.00-19.51-127.38-182.490.16-20.24-42.87-74.34
Sales/Maturities of Investments21.4614.89157.64-35.00181.36-7.5020.4043.1774.50
Other Investing Activities457.46215.436.51-39.47-136.00-7.33-1.660.300.16
Net Cash from Investing Activities375.09230.32144.64-166.85-138.41-14.40-12.73-1.19-4.42
Financing Activities
Debt Repayment-280.84-260.390.00-190.75-0.67222.1672.960.000.00
Common Stock Issued7.891.4674.229.3740.9021.238.15101.75206.85
Common Stock Repurchased0.000.00-3.59-3.74-1.75-0.880.000.00-0.54
Other Financing Activities-1.1234.05-1.03-1.23-2.43-18.568.263.670.48
Net Cash from Financing Activities-273.71-186.9769.6054.3351.88223.9589.37105.42206.79
Summary
Effect of Forex Changes on Cash0.000.00-0.010.000.000.00-0.280.47-0.12
Net Change in Cash-37.1322.9139.36-353.65-123.96363.69104.72-54.571.96
Cash at Beginning of Period126.25103.3463.55417.64541.60177.9173.19127.76124.95
Cash at End of Period89.12126.25102.8963.99417.64541.60177.9173.19126.91
Free Cash Flow-138.51-20.44-174.88-241.12-38.72146.9115.46-160.06-204.86
Supplemental Disclosures
Interest Paid-25.3837.8634.8818.6816.96---
Income Taxes Paid--0.11-0.120.041.223.95---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Coherus Oncology Cash Flow

What is Coherus Oncology's free cash flow?

Coherus Oncology had negative free cash flow of $138.51M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Coherus Oncology pay dividends or buy back shares?

Coherus Oncology's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition